Anrotinib combined with niraparib can achieve more favorable treatment results in some patients, and the efficacy needs to be evaluated based on the type of pathology of the patient as well as genetic testing. Anrotinib is a small molecule multi-target tyrosine kinase inhibitor, and niraparib is a PARP inhibitor, and studies have shown that the combination of the two in the treatment of platinum-resistant recurrent ovarian cancer has a disease control rate of about 85%, with no significant adverse effects. Of course, some patients are not sensitive to these treatments, so often the therapeutic effect is not ideal, but increase side effects and increase patient suffering. Therefore, it is necessary to carry out pathologic typing and genetic testing before using drugs, and only when corresponding indications are found can these drugs be used, so as to further prolong the survival period of patients. It is recommended that patients actively cooperate with the doctor’s treatment, so as not to delay the disease.